ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Athira Pharma Inc

Athira Pharma Inc (ATHA)

0.63
-0.015
(-2.33%)
Closed December 04 3:00PM
0.6175
-0.0125
(-1.98%)
After Hours: 6:23PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.6175
Bid
0.611
Ask
0.65
Volume
147,394
0.6107 Day's Range 0.6628
0.4115 52 Week Range 4.2984
Market Cap
Previous Close
0.645
Open
0.6377
Last Trade Time
Financial Volume
US$ 92,920
VWAP
0.630419
Average Volume (3m)
5,102,123
Shares Outstanding
38,669,073
Dividend Yield
-
PE Ratio
-0.21
Earnings Per Share (EPS)
-3.04
Revenue
1.63M
Net Profit
-117.67M

About Athira Pharma Inc

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease. Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Athira Pharma Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ATHA. The last closing price for Athira Pharma was US$0.65. Over the last year, Athira Pharma shares have traded in a share price range of US$ 0.4115 to US$ 4.2984.

Athira Pharma currently has 38,669,073 shares outstanding. The market capitalization of Athira Pharma is US$24.94 million. Athira Pharma has a price to earnings ratio (PE ratio) of -0.21.

ATHA Latest News

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0002-0.03237817710860.61770.67890.62957750.64608365CS
4-0.0219-3.425086018140.63940.82640.614687730.72571822CS
120.152532.79569892470.4650.82640.411551021230.60418454CS
26-1.9925-76.34099616862.613.670.411526975490.67935793CS
52-0.8625-58.2770270271.484.29840.411515282900.90755551CS
156-12.5025-95.29344512213.1214.220.41157413292.11611415CS
260-19.3325-96.904761904819.9534.790.41156853675.13327511CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZJKZJK Industrial Company Ltd
US$ 17.185
(171.06%)
28.21M
CTNTCheetah Net Supply Chain Service Inc
US$ 4.81
(157.22%)
113.16M
ORISOriental Rise Holdings Ltd
US$ 11.11
(69.10%)
1.47M
JYDJayud Global Logistics Ltd
US$ 1.1299
(68.62%)
10.8M
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.32M
REVBRevelation Biosciences Inc
US$ 0.504151
(-46.93%)
6.08M
OMEXOdyssey Marine Exploration Inc
US$ 0.4201
(-43.63%)
4.88M
RITRReitar Logtech Holdings Ltd
US$ 2.68
(-38.39%)
1.25M
XCURExicure Inc
US$ 14.05
(-37.00%)
433.62k
AGFYAgrify Corporation
US$ 32.72
(-36.69%)
285.46k
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.26M
SMCISuper Micro Computer Inc
US$ 40.21
(-4.26%)
200.61M
NVDANVIDIA Corporation
US$ 140.26
(1.18%)
162.81M
INTCIntel Corporation
US$ 22.47
(-6.10%)
135.91M
CHRSCoherus BioSciences Inc
US$ 1.7001
(24.09%)
113.52M

ATHA Discussion

View Posts
Rocket-Interceptor Rocket-Interceptor 4 weeks ago
just amazing
👍️0
glenn1919 glenn1919 4 weeks ago
ATHA................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 weeks ago
ATHA...........................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
ATHA TO A DOLLAR
👍️0
glenn1919 glenn1919 1 month ago
ATHA...........................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️ 1
stockyupydowny stockyupydowny 3 months ago
Some life coming back into play with this one, the 400 million cash injection deal that takes the to the $1 billion dollar deal they made will be reflected with patience
👍️ 1
Saving Grace Saving Grace 3 months ago
ATHA under .65 cents and plunging.
👍️0
Monksdream Monksdream 3 months ago
ATHA under $4
👍️0
Monksdream Monksdream 4 months ago
ATHA under $3
👍️0
Monksdream Monksdream 6 months ago
ATHA under $3
👍️0
glenn1919 glenn1919 8 months ago
ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 9 months ago
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
👍️0
Whalatane Whalatane 10 months ago
4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi
👍️0
Whalatane Whalatane 11 months ago
“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”


Kiwi
👍️0
Whalatane Whalatane 11 months ago
ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi
👍️0
Whalatane Whalatane 11 months ago
The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA... what a bio beast running through the streets...watch the explosion on the horizon...
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
What a day…what a stock!!!
👍️0
great_tree great_tree 3 years ago
Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA pushing hard into close
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA bio beast is very mad. She wants to fill that gap
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA is ready to move big next week, the best bio taking on Alzheimers
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA starting to heat up..love this bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA another bio beast ready to beast
👍️0
maximumgriff maximumgriff 3 years ago
Girt prices
👍️0
crudeoil24 crudeoil24 4 years ago
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
👍️0
crudeoil24 crudeoil24 4 years ago
Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.
👍️0

Your Recent History

Delayed Upgrade Clock